UPGL00004

製品コードS8778 バッチS877801

印刷

化学情報

Synonyms

N/A

Storage
(From the date of receipt)

3 years -20°C powder

化学式

C₂₅H₂₆N₈O₂S₂

分子量

534.66

CAS No.

1890169-95-5

Solubility (25°C)*

体外

DMSO

25 mg/mL (46.75 mM)

Water

Insoluble

Ethanol

Insoluble

体内（毎回新しく調製した物を用意してください）

Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O この製剤はselleckのラボで検証済みです。上記の溶解方法がご要望を満たさない場合、selleckの営業担当までお問い合わせ頂ければ、個別の試験を行います。	1.250mg/ml (2.34mM)	Taking the 1 mL working solution as an example, add 50 μL of 25 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil この製剤はselleckのラボで検証済みです。上記の溶解方法がご要望を満たさない場合、selleckの営業担当までお問い合わせ頂ければ、個別の試験を行います。	0.104mg/ml (0.19mM)	Taking the 1 mL working solution as an example, add 50 μL of 2.08 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明	UPGL00004 is a potent glutaminase C (GAC) inhibitor with an IC50 of 29 nM, showing high selectivity for GAC over GLS2.
in vitro	UPGL00004 potently inhibits the growth of triple negative breast cancer cells, as well as tumor growth when combined with the anti-VEGF antibody bevacizumab^[2].
in vivo	UPGL00004 potently suppresses tumor growth in a patient-derived xenograft model for breast cancer, when combined with the anti-angiogenesis, anti-VEGF monoclonal antibody bevacizumab^[2].

プロトコル(参考用のみ)

細胞アッセイ	細胞株	Breast cancer cells
	濃度	0-10 μM
	反応時間	6 days
	実験の流れ	Breast cancer cells are maintained in complete media (RPMI 1640 supplemented with 10% FBS) at 37°C and in a 5% CO2 atmosphere. For assays, cells are distributed into the wells of a 12 well plate at a density of 1 × 10⁴ cells per well. The cells are allowed to attach to the plate overnight, and then are treated for 6 days with the indicated amounts of each drug, or a DMSO control, in complete media. The media and drugs are refreshed every two days. On the sixth day, the cells are removed from the plates with trypsin, and counted manually with a hemocytometer.
動物実験	動物モデル	triple-negative breast cancer patient-derived tumor graft (PDX) model (NOD/SCID mice)
	投薬量	1 mg/kg
	投与方法	i.p.

参考

https://pubmed.ncbi.nlm.nih.gov/26988803/
https://pubmed.ncbi.nlm.nih.gov/29317493/

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。